United States securities and exchange commission logo





                          December 28, 2022

       Richard Paulson
       President and Chief Executive Officer
       Karyopharm Therapeutics Inc.
       85 Wells Avenue, 2nd Floor
       Newton, MA 02459

                                                        Re: Karyopharm
Therapeutics Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed December 23,
2022
                                                            File No. 333-268991

       Dear Richard Paulson:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Craig Hilts, Esq.